

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7227062

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BENOÎT SALOMON	01/13/2022
RECEIVING PARTY DATA	
Name:	UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Street Address:	61 AVENUE DU GÉNÉRAL DE GAULLE
City:	CRETEIL
State/Country:	FRANCE
Postal Code:	94000
Name:	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Street Address:	101 RUE DE TOLBIAC
City:	PARIS
State/Country:	FRANCE
Postal Code:	75013
Name:	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Street Address:	3 AVENUE VICTORIA
City:	PARIS
State/Country:	FRANCE
Postal Code:	75004
Name:	SORBONNE UNIVERSITE
Street Address:	21 RUE D'ECOLE DE MÉDECINE
City:	PARIS
State/Country:	FRANCE
Postal Code:	75006
Name:	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Street Address:	3 RUE MICHEL-ANGE
City:	PARIS
State/Country:	FRANCE
Postal Code:	75016
PROPERTY NUMBERS Total: 1	

Property Type	Number
Application Number:	16312647
CORRESPONDENCE DATA	
Fax Number:	(617)309-2601
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-309-2607
Email:	lpennybaker@verrill-law.com
Correspondent Name:	LIN J. HYMEL
Address Line 1:	VERRILL DANA LLP
Address Line 2:	ONE FEDERAL STREET, 20TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	21721-0401-FIVE
NAME OF SUBMITTER:	LIN J. HYMEL
SIGNATURE:	/Lin J. Hymel/
DATE SIGNED:	03/16/2022
Total Attachments: 2	
source=Signed assignment-Benoit Salomon#page1.tif	
source=Signed assignment-Benoit Salomon#page2.tif	

ASSIGNMENT

I,

Benoît SALOMON,

residing at

110 avenue de Condé
94100 Saint-Maur
France

Assignor, for good and valuable consideration, receipt of which is hereby acknowledged, hereby sell, assign, and transfer to **UNIVERSITE PARIS EST CRETEIL VAL DE MARNE** a French university, having a principal place of business at 61 avenue du Général de Gaulle, 94000 Creteil, France, **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)** a French research organization, having a principal place of business at 101 rue de Tolbiac, 75013 Paris, France, **ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS** a French hospital, having a principal place of business at 3 avenue Victoria, 75004 Paris, France, **SORBONNE UNIVERSITE** a French university, having a principal place of business at 21 rue d'Ecole de Médecine, 75006 Paris, France, and **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** a French research organization, having a principal place of business at 3 rue Michel-Ange, 75016, Paris, France (Assignees), as joint owners, and their successors and assigns, the entire right, title and interest in and to the invention

**Prevention or Treatment of Hematologic Malignancy Relapse
Using a TNFR2 Antagonist**

and to the patent application filed therefor, **U.S. Application No. 16/312,647**, filed on **December 21, 2018**, and any other patent applications filed therefor, and such patents, reissues, reexaminations, and extensions thereof which issue in any country upon said patent applications, which correspond with or claim priority from said applications, or any divisional, continuation, or continuation-in-part thereof, including the right to sue and collect for past infringement; the same to be held and enjoyed by Assignee for its own use, and for the use of its legal representatives, to the full term for which such patents are entitled, as fully and entirely as the same would have been held by me had this assignment not been made.


I hereby further covenant and agree that I will not execute any writing or do any act whatsoever conflicting with this agreement, and that I, my successors and assigns, will at any time upon request without further additional consideration, but at the expense of Assignee, its successors and assigns, execute such additional writings and do such additional acts as Assignee, its successors and assigns, may determine as necessary or desirable in the enjoyment of this grant, and in any proceedings or transactions involving such invention, patent applications or patents.

By:



Benoît SALOMON

Date: 13 January 2022



(Witness Signature)

MILAIRE DORGANE

(Witness Printed Name)